We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Prognostic significance of TRAIL death receptorsin Middle Eastern colorectal carcinomas and theircorrelation to oncogenic KRAS alterations.
- Authors
Bavi, Prashant; Prabhakaran, Sarita E.; Abubaker, Jehad; Qadri, Zeeshan; George, Thara; Al-Sanea, Nasser; Abduljabbar, Alaa; Ashari, Luai H.; Alhomoud, Samar; Al-Dayel, Fouad; Hussain, Azhar R.; Uddin, Shahab; Al-Kuraya, Khawla S.
- Abstract
Background: Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) is a member of the tumour necrosis factor cytokine family that induces apoptosis upon binding to its death domain containing receptors, TRAIL receptor 1 (DR4) and TRAIL receptor 2 (DR5). Expression of TRAIL receptors is higher in colorectal carcinoma (CRC) as compared to normal colorectal mucosa and targeted therapy with TRAIL leads to preferential killing of tumor cells sparing normal cells. Methods: We investigated the expression of TRAIL and its receptors in a tissue microarray cohort of 448 Middle Eastern CRC. We also studied the correlation between TRAIL receptors and various clinico-pathological features including key molecular alterations and overall survival. Results: CRC subset with TRAIL-R1 expression was associated with a less aggressive phenotype characterized by early stage (p = 0.0251) and a histology subtype of adenocarcinomas (p = 0.0355). Similarly CRC subset with TRAILR2 expression was associated with a well-differentiated tumors (p < 0.0001), histology subtype of adenocarcinomas (p = 0.0010) and tumors in left colon (p = 0.0009). Over expression of pro apoptotic markers: p27KIP1 and KRAS4A isoforms was significantly higher in CRC subset with TRAIL-R1 and TRAIL-R2 expression; TRAIL-R1 expression was also associated with cleaved caspase-3(p = 0.0011). Interestingly, TRAIL-R2 expression was associated with a microsatellite stable (MS-S/L) phenotype (p = 0.0003) and with absence of KRAS mutations (p = 0.0481). Conclusion: TRAIL-R1 expression was an independent prognostic marker for better survival in all CRC samples and even in the CRC group that received adjuvant therapy. The biological effects of TRAIL in CRC models, its enhancement of chemosensitivity towards standard chemotherapeutic agents and the effect of endogenous TRAIL receptor levels on survival make TRAIL an extremely attractive therapeutic target.
- Subjects
COLON cancer; TUMOR necrosis factors; APOPTOSIS; CYTOKINES; MUCOUS membranes
- Publication
Molecular Cancer, 2010, Vol 9, p203
- ISSN
1476-4598
- Publication type
Article
- DOI
10.1186/1476-4598-9-203